Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes.

Additional changes could make the registries of drug patents published by the FDA, called the Orange and Purple Books, more useful and reduce barriers to effective competition from generic and biosimilar drugs. [ABSTRACT FROM AUTHOR]